In Denmark, the regulatory action was associated with a significant immediate fall in diclofenac initiation in people with osteoarthritis and change to a negative trend in people with osteoarthritis and inflammatory arthropathies compared with baseline ( Table S2 ).
← all excerpts
Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands.
1
—
—